Purpose-built
The Haystack MRD difference
MRD testing demands high-sensitivity ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.
Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients.
Guide treatment with Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions.
-
Exceptional sensitivity
-
Tumor informed
-
Personalized
Prioritized patient access with The power of Quest
End-to-end reliability powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, test menu, and technology. Haystack MRD is seamlessly integrated into Quest Diagnostics advanced oncology testing for easy access and reliability.
Purpose built
The Haystack MRD difference
MRD testing demands high-sensitivity ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of ctDNA to uncover residual disease after definitive surgery.
- Innovation and leadership
-
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients. - Confident MRD results
-
Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions.-
Exceptional sensitivity
-
Tumor informed
-
Personalized
-
Track 50 variants
-
- The power of Quest
A track record of Innovation and leadership
Haystack MRD is the product of more than 20 years of pioneering work in liquid biopsy technologies and is purpose-built for ultrasensitive ctDNA detection.
Haystack MRD has been developed on the foundational work of cancer genomics pioneers, whose discoveries have transformed clinical practice for cancer patients.
Confident MRD results
Haystack MRD’s technology enables ultrasensitive ctDNA testing with the ability to detect 95% of cases at 0.0006% tumor fraction. With an exceptionally low limit of detection, you can uncover the insights you need to help make confident treatment decisions.
-
Exceptional sensitivity
-
Tumor informed
-
Personalized
-
Track 50 variants
Industry upates
Recent news
Find out what’s happening at Haystack Oncology and stay up-to-date with industry news.
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize postoperative therapy decisions in patients with stage II/III non-small cell lung cancer (NSCLC). Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center.
A paradigm shift in cancer care: Patients with select tumors successfully treated by immunotherapy alone
In a landmark study, many patients with mismatch repair–deficient (dMMR, also known as MMRd) cancers were effectively treated with immunotherapy alone, without surgery, chemotherapy, or radiation. 100% of patients with dMMR rectal cancer, and around 2/3 of patients with other dMMR cancers, had no sign of cancer after immunotherapy—without having to undergo life-altering surgery.1 These results not only show that immunotherapy alone can be effective in dMMR cancers, but also highlight the role of circulating tumor DNA (ctDNA) as a promising biomarker to track how cancers respond to treatment.
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.